University of Maryland School of Medicine

What University of Maryland School of Medicine does

The University of Maryland School of Medicine (UMSOM), founded in 1807 as the first public medical school in the United States, is a state-funded academic medical institution within the University System of Maryland, headquartered in Baltimore. It delivers medical education through a four-year MD program, eight combined MD/Masters dual-degree tracks (including MD/MBA, MD/MPH, MD/MSCI), residency and fellowship programs across specialties, graduate education, and pipeline programs such as the UM Scholars Summer Research Program in partnership with the University of Maryland College Park under MPower. Its research enterprise spans 27 academic departments and 12 core institutes and centers, including the Center for Vaccine Development and Global Health (CVD), the Institute for Genome Sciences (IGS), the Institute of Human Virology (IHV), the Maryland Psychiatric Research Center, the Center for Shock, Trauma and Anesthesiology Research (STAR), and the Center for Stem Cell Biology & Regenerative Medicine. Notable in-house technologies include the TetherChip device for detecting microtentacles on circulating breast cancer cells, the RcoM-HBD-CCC protein-based carbon monoxide antidote therapy, and the LASSARAB inactivated rabies-virus-vectored Lassa fever vaccine candidate, which achieved 100% Lassa seroconversion and 100% rabies seroprotection in a 54-participant Phase 1 trial.

UMSOM's revenue model is a hybrid of federal and state research funding, tuition, clinical service revenue routed through affiliated hospitals, and philanthropic giving. In FY2025, researchers at the school drew $501.2M in total grants and contracts, with NIH as the dominant funder (a single $14.5M five-year award supports the Human Virome Program data center). State appropriations fund capital programs such as the Center for Combat Casualty Care ($1M) and advanced microscopy ($2.9M federal). Clinical revenue flows through the University of Maryland Medical Center, the R Adams Cowley Shock Trauma Center (which invented the shock trauma field and is among the largest U.S. organ transplant centers), the UM Marlene and Stewart Greenebaum Comprehensive Cancer Center (an NCI-designated comprehensive center offering cell and gene therapies), and community-facing programs including Mobile Healthcare Baltimore and the National Center for School Mental Health. The institution is led by Dean Mark Gladwin, MD, and is governed under the University of Maryland, Baltimore (UMB) umbrella.

The school's go-to-market operates across three concurrent planes: attracting MD and graduate applicants (average applicant GPA of 3.84 in the MD Program, 217th graduating class), recruiting patients regionally through UMMC and Shock Trauma, and competing for federal grants and industry partnerships. Recent strategic positioning includes the 2022 first-ever pig-to-human heart transplant, first drone-delivered kidney for transplantation, and a first-in-human unique RNA COVID-19 vaccine, alongside newer moves such as the joint venture with Axis Research & Technologies to build an AI-powered Smart Surgical Performance Center (construction starting 2026) and the Baszucki Group partnership on ketogenic metabolic therapy clinician training. The institution is privately classified by the firmographic record but publicly governed as part of the state university system and does not have PE/VC ownership.

Name

University of Maryland School of Medicine

Legal name

University of Maryland School of Medicine

Website

https://medschool.umaryland.edu

Company type

Private

Founded year

1807

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

The University of Maryland School of Medicine is a public academic medical school in Baltimore founded in 1807 that delivers MD, dual-degree, residency, and graduate education, runs a $501.2M research enterprise across 12 institutes, and provides clinical care through the University of Maryland Medical Center and R Adams Cowley Shock Trauma Center.

Ownership category

akta.pro rank

Product category

Medical Education and Biomedical Research

NAICS

Colleges, Universities, and Professional Schools (6113), Scientific Research and Development Services (5417)

SIC

Services-Hospitals (8060), Services-Commercial Physical & Biological Research (8731), Services-Offices & Clinics Of Doctors Of Medicine (8011)

akta.pro primary industry

Medical Schools (MD/DO Granting) (EDAHAGAB)

akta.pro secondary industries

Academic Medical Centers & Teaching Hospitals (University-Affiliated) (EDAHAGAA), Biomedical Sciences & Medical Research Institutes (University-Based) (EDAHAGAI), Public Research Universities with Academic Medical Centers (AMCs) (EDAHAAAC), Healthcare Clinical Professions (CME/CE for Nurses, Allied Health, Pharmacy) (EDAAALAC)

Keywords

• Medical education
• Biomedical research
• Clinical care services
• Vaccine development
• Graduate medical training

Headquarters

HQ city

Baltimore

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B and B2C

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Supply Chain, Marketing or Sales, Others

Distribution channels5 records

Marketing channels7 records

Core offering

The University of Maryland School of Medicine is a public academic medical institution that delivers medical education (MD, MD/Masters combined degrees, residency, fellowship, and graduate programs), conducts biomedical and translational research through twelve research centers and institutes, and provides specialty clinical care through affiliated hospitals including the R Adams Cowley Shock Trauma Center and the UM Marlene and Stewart Greenebaum Comprehensive Cancer Center. The school develops vaccines and therapeutics (e.g., LASSARAB vaccine, RcoM-HBD-CCC carbon monoxide antidote, TetherChip device) and operates NIH-funded multi-site research programs such as the Human Virome Program.

Product overview

The University of Maryland School of Medicine is a major academic medical institution offering a comprehensive portfolio of educational programs, research capabilities, and clinical services. The core offering is the Doctor of Medicine (MD) program, supplemented by MD/Masters dual degree programs (MD/MBA, MD/MPH, MD/MSCI, etc.), residency and fellowship programs, and graduate education. Research infrastructure includes the Center for Vaccine Development and Global Health (CVD) developing vaccines for global health threats, the Institute for Genome Sciences (IGS) with NIH-funded Human Virome Program, and the Institute of Human Virology (IHV). Clinical services are provided through the R Adams Cowley Shock Trauma Center (inventor of shock trauma medicine), the UM Marlene and Stewart Greenebaum Comprehensive Cancer Center (offering cell and gene therapies), and numerous specialty programs. Recent innovations include the LASSARAB vaccine candidate, AI-powered surgical technology through a joint venture with Axis Research & Technologies, and ketogenic metabolic therapy training. The institution achieved historic firsts including the first pig-to-human heart transplant (2022) and first drone kidney delivery for transplantation.

Differentiator

Problem solved

Functional benefit

Products and services

• Doctor of Medicine (MD) Program Four-year medical degree program preparing students to become physicians, scientists, and allied health professionals at the first public medical school in the United States.
• MD/Masters Dual Degree Programs Combined degree programs including MD/MBA, MD/MHA, MD/MPH, MD/MPP, MD/MS BIOE, MD/MS CMBS, MD/MSCI, MD/MSCR, and MD/MS-HPE for students seeking additional expertise alongside the MD degree.
• Residency Programs Postgraduate medical training programs across multiple specialties offered through the University of Maryland School of Medicine and affiliated hospitals.
• Fellowship Programs Specialized postdoctoral training programs for physicians seeking subspecialty expertise in fields such as trauma, oncology, and infectious disease.
• Graduate Education Programs Graduate programs (MS, PhD) in life sciences and biomedical research disciplines, including genetic counseling, pathologists' assistant, physical therapy, and public health.
• LASSARAB Vaccine Inactivated rabies virus-vectored Lassa virus vaccine candidate developed for dual protection against rabies and Lassa fever, currently in Phase 1 clinical trials at the Center for Vaccine Development and Global Health.
• Center for Vaccine Development and Global Health (CVD) Research center conducting vaccine development for global health threats including malaria, Ebola, COVID-19, cholera, MERS/SARS, influenza, and typhoid, with a proven track record in first-in-human clinical trials.
• Institute for Genome Sciences (IGS) Research institute focused on genomics, computational biology, and large-scale consortium data analysis, recipient of a $14.5 million NIH grant to establish the Consortium Organization and Data Collaboration Center for the Human Virome Program.
• Institute of Human Virology (IHV) Institute dedicated to virology research and infectious disease studies, including HIV/AIDS research and global health virology programs.
• R Adams Cowley Shock Trauma Center World-renowned trauma center that invented the field of Shock Trauma and operates as one of the largest organ transplant centers in the United States.
• UM Marlene and Stewart Greenebaum Comprehensive Cancer Center NCI-designated comprehensive cancer center offering innovative cancer treatments including cell therapies for synovial sarcoma and gene therapy for sickle cell disease.
• National Center for School Mental Health Center focused on strengthening school-based mental health services, funded by the Annie E. Casey Foundation to provide guidance on mental health systems for students in schools and communities.
• RcoM-HBD-CCC Carbon Monoxide Antidote Engineered protein-based therapy acting as a sponge to rapidly remove carbon monoxide from blood, showing promise as a faster, safer antidote for carbon monoxide poisoning with potential applications as a blood substitute.
• Ketogenic Metabolic Therapy Training Program Clinical training program for healthcare professionals on implementing personalized ketogenic metabolic therapy (ketogenic diets) to treat mental illnesses including schizophrenia, bipolar disorder, and major depressive disorder.

Segments5 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Eight partnerships are on record, tiered core.

• Baszucki GroupcoreStrategic or Co-development Partner · 4 December 2025The University of Maryland School of Medicine partnered with Baszucki Group to launch an innovative clinician training program on ketogenic metabolic therapy for mental health care. The initiative aims to educate healthcare professionals on implementing personalized ketogenic diets to treat mental illnesses such as schizophrenia, bipolar disorder, and major depressive disorder.
• Axis Research & TechnologiescoreStrategic or Co-development Partner · 20 October 2025The University of Maryland, Baltimore and Axis Research & Technologies announced a joint venture to create the nation's first AI-powered smart surgical performance center in Baltimore. The 36,000 sq. ft. facility will utilize OMNIMED SmartOR technology to enhance surgical training, research, and patient care, with construction expected to start in 2026.
• MPowering the State (MPower)coreStrategic or Co-development PartnerThe University of Maryland Strategic Partnership: MPowering the State supports the UM Scholars Summer Research Program, enabling University of Maryland College Park (UMCP) undergraduates to engage in research at UMSOM. The partnership provides funding and administrative support for pipeline programs connecting UMCP students to medical research careers.
• Broad InstitutecoreStrategic or Co-development PartnerCollaborating research institution for the NIH-funded Human Virome Program. The IGS team collaborates with researchers from Broad Institute as part of a research network spanning 16 locations across different ages, sexes, ancestries, and geographic areas to create a publicly accessible Human Virome Reference Dataset.
• Harvard T.H. Chan School of Public HealthcoreStrategic or Co-development PartnerCollaborating research institution for the NIH-funded Human Virome Program. The IGS team collaborates with Harvard researchers as part of a research network spanning 16 locations to create a publicly accessible Human Virome Reference Dataset and standardized analysis toolkit.
• Washington University in St. LouiscoreStrategic or Co-development PartnerCollaborating research institution for the NIH-funded Human Virome Program. The IGS team collaborates with Washington University researchers to develop new analytics tools and a user-friendly portal for virome data analysis.
• Baylor College of MedicinecoreStrategic or Co-development PartnerCollaborating research institution for the NIH-funded Human Virome Program. The IGS team collaborates with Baylor College of Medicine as part of the 16-location research network for the Human Virome Program.
• Lawrence Berkeley National LaboratorycoreStrategic or Co-development PartnerCollaborating research institution for the NIH-funded Human Virome Program. The IGS team collaborates with Lawrence Berkeley National Laboratory researchers to create a publicly accessible Human Virome Reference Dataset and standardized analysis toolkit.

Scale indicators9 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Vagelos College of Physicians and Surgeons (Columbia University): Research-intensive medical school in a major U.S. metro with affiliated hospital (NewYork-Presbyterian). Comparable in MD/PhD training, biomedical research funding scale, and academic medical center structure.
• Perelman School of Medicine at the University of Pennsylvania: Elite private research medical school with extensive NIH funding, affiliated hospital (Penn Medicine), and a similarly broad biomedical research and clinical portfolio. Highly comparable in academic medical center operating model and grant scale.
• Duke University School of Medicine: Top-tier U.S. medical school with strong NIH funding, affiliated academic medical center, and dual-degree programs. Comparable in research output, MD curriculum structure, and translational research focus.
• Emory University School of Medicine: Major Southeast-based academic medical center with CDC proximity, vaccine/infectious disease expertise (including HIV and Ebola work), and a similar portfolio of NIH-funded global health research. Highly comparable on vaccine development and global health mission.
• Harvard Medical School: The largest U.S. medical school by research funding, with multiple affiliated teaching hospitals and a broad biomedical research portfolio. Direct comparable in MD training, NIH grant scale, and global health partnerships (overlaps with UMSOM on Human Virome).
• Stanford University School of Medicine: Top U.S. research medical school with affiliated hospital, large NIH portfolio, and a strong translational/biotech interface. Comparable in academic medical center operations, research funding scale, and innovation pipeline.
• Johns Hopkins University School of Medicine: Also a top-tier Baltimore-based research medical school with affiliated hospital system (Johns Hopkins Hospital). Directly comparable in MD/PhD training, NIH funding scale, biomedical research output, and clinical service portfolio; UMSOM's most direct local competitor.

Regional players

• University of Virginia School of Medicine: Public medical school in the Mid-Atlantic region with a comparable research and training footprint. Operates in overlapping regional catchment but with a smaller research portfolio; useful Mid-Atlantic public school benchmark.
• Georgetown University School of Medicine: D.C.-area medical school with affiliated clinical system and similar MD/dual-degree offerings. Comparable in scale and urban academic medical center profile, though smaller research portfolio than UMSOM.

Broad incumbents

• National Institutes of Health (NIH) Intramural Research Program: Largest single biomedical research funder in the U.S. and the primary grantor for UMSOM's research enterprise. Comparable as a research and training organization but federal rather than academic; relevant for benchmarking federal funding dynamics that drive UMSOM revenue.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xx.com/ummedschool
• YouTubeyoutube.com/schoolofmedicine
• Facebookfacebook.com/Maryland.Medicine
• Instagraminstagram.com/Marylandmedicine

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Subsidiaries12 records

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about University of Maryland School of Medicine